Adiso Therapeutics

At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.

To tackle these challenges, we are advancing an innovative pipeline of multi-modal agents all with novel mechanisms of action and a precision therapeutic approach.

• ADS032 is a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.
• ADS024 is an orally dosed, naturally occurring single-strain live biotherapeutic product (SS-LBP) that exerts its effects through selective agonism of a G-protein coupled receptor. It has demonstrated efficacy in multiple neurodegenerative disease models across 12 separate animal studies, representing 8 distinct neurodegenerative and neuroinflammatory diseases.